Eli Lilly and Co.

FDA set to review testosterone-boosting drug usage

September 16, 2014
Bloomberg News
Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.
More

Lilly to pay AstraZeneca up to $500M in Alzheimer’s push

September 16, 2014
Bloomberg News
The two companies will work together to develop AZD3293, which belongs to a novel class of drugs called BACE inhibitors that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
More

Recent wins worth $4B to Lilly market value

September 15, 2014
J.K. Wall
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
More

Lilly execs make pitch for local preschool education

September 12, 2014
Jared Council
Eli Lilly and Co. executives on Friday repeated their plea to local businesses to support early childhood education, highlighting the work force development and crime-reduction benefits associated with the effort.
More

Lilly cancer drug fares well in late-stage study

September 12, 2014
Associated Press
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
More

Lilly says new insulin fares better than rival's in late-stage tests

September 4, 2014
Associated Press
The Indianapolis-based drugmaker said Thursday that peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
More

Lilly, partner lose appeal to overturn $9 billion Actos court award

August 28, 2014
Bloomberg News
Takeda Pharmaceutical Co. and Eli Lilly and Co. lost a bid to have a judge throw out a combined $9 billion punitive-damage award over claims the drugmakers hid the cancer risks of their Actos diabetes medicine.
More

A love story with Christ Church takes contentious turn

August 23, 2014
Greg Andrews
This is far from the first time that heirs and beneficiaries of the Lilly family fortune have tangled over how it was managed.
More

After strong trials, Lilly to seek approvals for psoriasis drug

August 21, 2014
J.K. Wall
The drug company said Thursday its drug ixekizumab cleared away skin inflammation in six times as many patients as the blockbuster drug Enbrel. Lilly is in a race to bring the first in a new-class of psoriasis treatments to market.
More

Lilly wins tentative approval for diabetes drug

August 20, 2014
 IBJ Staff
Final approval could be delayed until mid-2016 due to a claim of patent infringement by drugmaker Sanofi.
More

Lilly among those eyeing antibiotic maker Cubist, analyst says

August 18, 2014
Bloomberg News
The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020.
More

Eli Lilly making renewed push in biotech field, where it once pioneered

August 16, 2014
J.K. Wall
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
More

Eli Lilly to close Terre Haute animal enzyme plant

August 14, 2014
Associated Press
The plant closure will affect 23 plant employees, all of whom will be offered comparable positions at a Lilly plant near Clinton that employs about 500 workers.
More

FDA approves Lilly, Boehringer diabetes drug

August 1, 2014
Associated Press
The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes who also are trying to control their condition with diet and exercise.
More

Roche drug trial backs Lilly on Alzheimer’s findings

July 28, 2014
J.K. Wall
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer's.
More

Report: Indiana boasts four nation-leading life sciences clusters

June 30, 2014
J.K. Wall
The areas around each of Indiana’s research university campuses—Bloomington, Indianapolis, Lafayette and South Bend—all boast outsize concentration of life sciences workers. Yet the state still lags on research, development and investment funding.
More

Lilly wins EU backing for version of insulin drug

June 27, 2014
Bloomberg News
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
More

Lilly, IU expect $25M plan to create new model for drug R&D

June 16, 2014
J.K. Wall
A new research consortium spearheaded by the Indiana University School of Medicine and Eli Lilly and Co. could bring in $25 million to $50 million over five years to create a new approach for developing drugs that provide more precise treatment for small groups of patients.
More

Former Riley Hospital CEO Pescovitz to join Eli Lilly

June 11, 2014
J.K. Wall
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
More

Lilly consolidated into testosterone drug lawsuit

June 9, 2014
Bloomberg News
The decision to collect cases before one court comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
More

Costly drugs force cancer docs to weigh price with therapy

May 30, 2014
Bloomberg News
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
More

Lilly, Sanofi seek to sell erection drug Cialis without prescription

May 28, 2014
 Bloomberg News and IBJ Staff
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
More

Ex-Lilly partner wins latest suit over Actos' cancer risk

May 23, 2014
Bloomberg News
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company's latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
More

Takeda denies hiding Actos cancer risks in Nevada trial

May 21, 2014
Associated Press
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
More

Drugmaker hid diabetes drug’s cancer risks, lawyer says

May 19, 2014
Bloomberg News
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
More
Page  1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT